141 related articles for article (PubMed ID: 6381383)
1. Toxicity of ASTA Z 7557 (INN mafosfamide) to normal- and leukemic stem cells: implications for autologous bone marrow transplantation.
Hagenbeek A; Martens AC
Invest New Drugs; 1984; 2(2):237-43. PubMed ID: 6381383
[TBL] [Abstract][Full Text] [Related]
2. Cryopreservation of autologous marrow grafts in acute leukemia: survival of in vivo clonogenic leukemic cells and normal hemopoietic stem cells.
Hagenbeek A; Martens AC
Leukemia; 1989 Jul; 3(7):535-7. PubMed ID: 2659904
[TBL] [Abstract][Full Text] [Related]
3. Autologous bone marrow transplantation for acute leukemia using transplant chemopurified with metabolite of oxazaphosphorines (ASTA Z 7557, INN mafosfamide). First clinical results.
Hervé P; Cahn JY; Plouvier E; Flesch M; Tamayo E; Leconte des Floris R; Peters A
Invest New Drugs; 1984; 2(2):245-52. PubMed ID: 6381384
[TBL] [Abstract][Full Text] [Related]
4. ASTA Z 7557 (INN mafosfamide) for the in vitro treatment of human leukemic bone marrows.
Douay L; Gorin NC; Laporte JP; Lopez M; Najman A; Duhamel G
Invest New Drugs; 1984; 2(2):187-90. PubMed ID: 6381382
[TBL] [Abstract][Full Text] [Related]
5. In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213).
Deconinck E; Tamayo E; Hervé P
Bone Marrow Transplant; 1990 Jan; 5(1):13-8. PubMed ID: 2297586
[TBL] [Abstract][Full Text] [Related]
6. Autologous bone marrow transplantation using marrow incubated with Asta Z 7557 in adult acute leukemia.
Gorin NC; Douay L; Laporte JP; Lopez M; Mary JY; Najman A; Salmon C; Aegerter P; Stachowiak J; David R
Blood; 1986 May; 67(5):1367-76. PubMed ID: 3516254
[TBL] [Abstract][Full Text] [Related]
7. Effect of mafosfamide (ASTA-Z-7654) on the clonogenic cells in precursor-B acute lymphoblastic leukaemia: significance for ex vivo purging of bone marrow for autologous transplantation.
Makrynikola V; Kabral A; Bradstock KF
Bone Marrow Transplant; 1991 Nov; 8(5):351-5. PubMed ID: 1768969
[TBL] [Abstract][Full Text] [Related]
8. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
9. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
10. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
Kohn FR; Sladek NE
Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
[TBL] [Abstract][Full Text] [Related]
11. No preferential sensitivity of clonogenic AML cells to ASTA-Z-7557.
Kluin-Nelemans HC; Martens AC; Löwenberg B; Hagenbeek A
Leuk Res; 1984; 8(4):723-8. PubMed ID: 6590937
[TBL] [Abstract][Full Text] [Related]
12. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
13. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
[TBL] [Abstract][Full Text] [Related]
14. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
Lopez M; Mary JY; Sainteny F
Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567
[TBL] [Abstract][Full Text] [Related]
15. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro effects of cyclophosphamide derivatives on murine bone marrow-derived stromal and hemopoietic progenitor cell classes.
de Jong JP; Nikkels PG; Brockbank KG; Ploemacher RE; Voerman JS
Cancer Res; 1985 Sep; 45(9):4001-5. PubMed ID: 3896474
[TBL] [Abstract][Full Text] [Related]
17. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
Grant S; Bhalla K; Arlin Z; Howe CW
Exp Hematol; 1990 Jan; 18(1):41-8. PubMed ID: 2298268
[TBL] [Abstract][Full Text] [Related]
18. Effect of two cyclophosphamide derivatives on hemopoietic progenitor cells and pluripotential stem cells.
Porcellini A; Manna A; Talevi N; Sparaventi G; Marchetti-Rossi MT; Baronciani D; De Biagi M
Exp Hematol; 1984 Dec; 12(11):863-6. PubMed ID: 6510485
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic bone marrow purging: is there any place for etoposide? In vitro comparison with mafosfamide.
Olivieri A; Poloni A; Montanari M; Cantori I; Corvatta L; Masia MC; Curzi L; Mancini S; Leoni P
J Hematother; 1997 Apr; 6(2):137-44. PubMed ID: 9131443
[TBL] [Abstract][Full Text] [Related]
20. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow.
Mumcuoglu M; Naparstek E; Slavin S
Bone Marrow Transplant; 1990 Mar; 5(3):153-8. PubMed ID: 2184907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
